TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2377
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab ; volume:12 ; number:1 ; day:18 ; month:9 ; year:2012 ; pages:1-6 ; date:12.2012
BMC neurology ; 12, Heft 1 (18.9.2012), 1-6, 12.2012
- Creator
-
Oreja-Guevara, Celia
- Contributor
-
Ramos-Cejudo, Jaime
Aroeira, Luiz Stark
Chamorro, Beatriz
Díez-Tejedor, Exuperio
SpringerLink (Online service)
- DOI
-
10.1186/1471-2377-12-95
- URN
-
urn:nbn:de:1111-2016030330260
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Oreja-Guevara, Celia
- Ramos-Cejudo, Jaime
- Aroeira, Luiz Stark
- Chamorro, Beatriz
- Díez-Tejedor, Exuperio
- SpringerLink (Online service)
Other Objects (12)
Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Relapsing/remitting type 1 diabetes
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: a case report
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
Postural Control in Relapsing-Remitting Multiple Sclerosis
Endocarditis following ocrelizumab in relapsing-remitting MS
Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis
Intravenous or subcutaneous natalizumab in patients with relapsing–remitting multiple sclerosis: investigation on efficiency and savings—the EASIER study
Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Relapsing/remitting type 1 diabetes
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: a case report
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
Postural Control in Relapsing-Remitting Multiple Sclerosis
Endocarditis following ocrelizumab in relapsing-remitting MS
Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis
Intravenous or subcutaneous natalizumab in patients with relapsing–remitting multiple sclerosis: investigation on efficiency and savings—the EASIER study
Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Relapsing/remitting type 1 diabetes
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: a case report
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
Postural Control in Relapsing-Remitting Multiple Sclerosis
Endocarditis following ocrelizumab in relapsing-remitting MS
Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis